Shilpa Medicare Ltd (SHILPAMED) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Shilpa Medicare Ltd on NSE and BSE, with an AI summary of each filing.
SHILPA MEDICARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Investor conference call for Q2-FY27 is scheduled to be held on 05 November 2026.
Intimation · 05 Nov 2026, 4:00 pm
Shilpa Medicare Schedules Q2FY27 Earnings Conference Call for 5th Nov'26 Shilpa Medicare Limited will announce its financial results for the quarter and half year ended 30th Sep'26 on 5th Nov'26. Following the announcement, company management will host its Q2FY27 earnings conference call on Thursday, 5th Nov'26, at 16:00 hrs IST. Universal dial-in access numbers include +91 22 6280 1130 and +91 22 7115 8031, alongside dedicated international toll-free lines for key global markets including the US, UK, Singapore, and Hong Kong.
Shilpa Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 05 Nov 2026, 5:30 am
Shilpa Medicare Board to Consider Q2 and H1 Results on 5th Nov'26 Shilpa Medicare Limited will hold its Board of Directors meeting on 5th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for company securities has been closed since 1st Oct'26 and will remain closed until 7th Nov'26 (both days inclusive).
Europe GMP approval of Shilpa Medicare Limited. Unit 4, Jadcherla, Telangana.
Others (Uncategorized) · 10 Oct 2026, 6:10 pm
Shilpa Medicare Secures European GMP Certification for Jadcherla Facility Shilpa Medicare announced on 10th Oct'26 that its Unit 4 facility in Jadcherla, Telangana, has received GMP certification from AGES, Austria, following an inspection conducted between 27th Jul'26 and 30th Jul'26. The certified unit is engaged in the manufacturing, testing, and distribution of sterile injections alongside non-sterile tablets and capsule finished dosage forms targeted for Europe and rest-of-the-world (RoW) markets.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 26, 2026 for Ramakant Innani & Others
Encumbered Shares - Invocation / Release · 26 Sept 2026, 7:53 pm
Shilpa Medicare Promoters Release 1.53% Pledged Equity Stake Members of the Shilpa Medicare Limited promoter group released encumbrances on 30,00,000 equity shares, representing 1.5337% of the company's paid-up share capital, on 25th Sep'26. The pledge release, executed by lender Bajaj Finance Limited, involved key promoters including Vishnukant C Bhutada (10,00,000 shares / 0.5113%), Dharmavati Bhutada (6,00,000 shares / 0.3067%), Deepak Kumar Innani (5,00,000 shares / 0.2556%), Ramakant Innani (5,00,000 shares / 0.2556%), Omprakash Inani (2,00,000 shares / 0.10225%), and Brijgopal Innani (2,00,000 shares / 0.10225%). The released shares were previously encumbered as collateral for self-loans.
Assignment of ESG Ratings by CRISIL ESG Ratings
Others (Uncategorized) · 23 Sept 2026, 8:38 pm
CRISIL Assigns 'Crisil ESG 59' Score to Shilpa Medicare CRISIL ESG Ratings & Analytics has assigned Shilpa Medicare an ESG score of "Crisil ESG 59". The rating was derived from the company's FY26 disclosures and publicly available data. Shilpa Medicare confirmed it did not formally engage the agency for this assessment; the score was independently evaluated by CRISIL using public domain information, pursuant to SEBI Regulation 30 disclosure norms.
Investors/Analysts meet
Intimation · 22 Sept 2026, 9:15 pm
Shilpa Medicare to Attend Nuvama Emerging India CEO Forum in Mumbai Shilpa Medicare Limited will participate in-person at the Nuvama – Emerging India CEO Forum on 28th Sep'26 in Mumbai. Company officials are scheduled to engage with investors and analysts through 1x1 and group meeting formats. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions.
USFDA Inspection of Shilpa Medicare Limited at Unit VII, Analytical Services Division, Hyderabad.
Others (Uncategorized) · 19 Sept 2026, 12:24 am
USFDA Concludes Surveillance Inspection at Shilpa Medicare's Unit VII Analytical Facility The USFDA concluded a surveillance inspection at Shilpa Medicare's Unit VII Analytical Services Division in Hyderabad on 18th Sep'26 with one procedural observation. The observation is neither a repeat issue nor related to data integrity. The company plans to submit a response with corrective and preventive actions within the stipulated timeline and expects no material impact on current business operations or existing supplies from the facility.
Submission of Scrutinizers Report on 39th AGM Resolutions along with Voting Results
Annual General Meeting · 12 Sept 2026, 9:49 pm
Shilpa Medicare''s Novel Complex Injectable OERIS (Ondansetron Extended - Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing ....
Press Release · 11 Sept 2026, 6:55 pm
Shilpa Medicare Receives SEC Approval for Novel Injectable OERIS Shilpa Medicare received final approval on 11th Sep'26 from the Subject Expert Committee under CDSCO for marketing authorization of OERIS (Ondansetron Extended-Release Injection, 100 mg/mL). Designed as the world's first extended-release ondansetron injection, OERIS provides up to 120 hours of antiemetic protection from a single dose for chemotherapy-induced nausea and vomiting. Backed by successful Phase III trials, the product holds Indian patent protection until 2039. The company plans a commercial rollout across India upon receiving final marketing authorization from CDSCO.
Proceedings of 39th Annual General Meeting.
Annual General Meeting · 11 Sept 2026, 6:34 pm
Initiation of NCLT Order on FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited.
Others (Uncategorized) · 10 Sept 2026, 8:29 pm
NCLT Initiates CIRP Against Shilpa Medicare Subsidiary FTF Pharma Over ₹2.18 Crore Dues NCLT Ahmedabad Bench admitted a Section 9 IBC petition filed by Immacule Lifesciences against FTF Pharma, a wholly owned subsidiary of Shilpa Medicare, ordering Corporate Insolvency Resolution Process (CIRP) commencement on 9th Sep'26. The proceedings involve an outstanding operational debt of ₹2.18 Cr under a technology transfer agreement. NCLT imposed a statutory moratorium and appointed Sunil Kumar Kedia as Interim Resolution Professional. Shilpa Medicare stated no contravention was found against the listed entity, financial impact remains presently unascertainable, and it is consulting legal advisors.
Dispatch of letter to shareholders whose e-mail addresses are not registered with Company/ Registrar & Transfer Agent/ Depository Participants.
Others (Uncategorized) · 19 Aug 2026, 9:57 pm
Shilpa Medicare Announces 39th AGM and E-Voting Dates Shilpa Medicare will hold its 39th Annual General Meeting (AGM) via video conference on 11th Sep'26 at 11:00 AM. The company has dispatched the Annual Report for FY 2025-26 and the AGM notice. The cut-off date for determining shareholder eligibility for e-voting is 04th Sep'26. The remote e-voting window will be open from 09:00 AM on 07th Sep'26 until 05:00 PM on 10th Sep'26. This action complies with SEBI's LODR Regulations regarding shareholder communication.
Disclosure under Reg.30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Others (Uncategorized) · 18 Aug 2026, 9:40 pm
Shilpa Medicare Clarifies US Drug Recall; States No Material Financial Impact Shilpa Medicare, on Aug 18, '26, clarified a voluntary US recall of its Pemetrexed Injection initiated on Jul 29, '26. The recall involves 27,923 vials across four batches due to atypical discoloration. Classified by the US FDA as a Class II (hospital level) recall, it was undertaken cautiously, with no adverse events reported. The company stated the recall is confined to the specified batches and does not foresee any material impact on its financial position or operations, reassuring investors. The issue is product-specific and does not affect other products.
Dividend Update
Dividend · 17 Aug 2026, 9:25 pm
Shilpa Medicare Announces FY26 Dividend and Record Date Shilpa Medicare has declared a final dividend of ₹0.60 per equity share for FY26. The company set Fri, 04 Sep'26, as the record date to determine shareholder entitlement. The dividend payout is subject to shareholder approval at the Annual General Meeting scheduled for Fri, 11 Sep'26. As per tax regulations, the dividend is taxable in the hands of shareholders, and the company will deduct tax at source (TDS) at applicable rates. Shareholders must update their PAN and other details by the record date.
Annual Report of Shilpa Medicare Limited for the FY 2025-26
Others (Uncategorized) · 13 Aug 2026, 11:14 pm
39th Annual General Meeting Notice
Annual General Meeting · 13 Aug 2026, 11:02 pm
Q1FY27 earnings conference call transcript
Transcript · 10 Aug 2026, 9:23 pm
Audio link of the Investor Conference call for Q1 FY27
Audio / Video · 06 Aug 2026, 1:15 am
Shilpa Medicare Publishes Q1/FY27 Analyst Call Recording Shilpa Medicare (NSE: SHILPAMED) has released the audio recording of its Q1/FY2026-27 analyst and investor conference call. The call was held on 5th Aug'26 at 16:00 hrs. The recording is now available on the company's website for stakeholders, providing access to management's discussion and outlook for the quarter.
Investor Presentation for Q1FY27
Investor Presentation · 05 Aug 2026, 7:46 pm
Shilpa Medicare Reports Record Revenue and Strong YoY Growth in Q1FY27 Shilpa Medicare posted its highest-ever quarterly revenue of INR 469 cr in Q1FY27, a 43% YoY increase driven by growth across all verticals. Consolidated EBITDA grew 42% YoY to INR 139 cr with margins maintained at 30%. PAT soared 115% YoY to INR 101 cr. The Formulations business delivered robust growth of over 100% YoY, led by strong traction in the US, Europe, and domestic markets following the NorUDCA launch. The company's credit rating was also upgraded from A+ to AA-.
The record date for determining the shareholders entitled for payment of final dividend for FY 2025-26, if declared at the 39th AGM is Friday, 4th September 2026.
Dividend · 05 Aug 2026, 7:44 pm
Unaudited standalone and consolidated Financial Results for the Quarter ended 30 June 2026
Financial Result · 05 Aug 2026, 7:28 pm
Shilpa Medicare Q1FY27: Revenue Jumps, Subsidiary to Invest EUR 7M in G2B For Q1FY27, Shilpa Medicare reported consolidated net profit of ₹100.88 Cr and revenue from operations of ₹465.78 Cr, up 44.9% YoY. Standalone PAT was ₹64.92 Cr on revenue of ₹189.04 Cr, a 102.3% YoY increase. Key board decisions include a planned EUR 7 million investment by subsidiary Shilpa Biocare into Gate2Brain. A final dividend for FY26 was proposed, with a record date of 4th Sep'26. The 39th AGM is scheduled for 11th Sep'26.
Unaudited Financial Results for the Quarter ended 30 June 2026
Outcome · 05 Aug 2026, 7:20 pm
Shilpa Medicare Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 46,578 (+44.9% YoY | +6.6% QoQ) ■ EBITDA: 13,626 (+48.7% YoY | +13.8% QoQ) ■ EBITDA Margin (%): 29.3 (+75 bps YoY | +186 bps QoQ) ■ PAT: 10,088 (+115.2% YoY | -6.4% QoQ) ■ EPS (INR): 5.16 (+115.0% YoY | -6.4% QoQ)
Appointment of Dr. Uday N. Harle as Chief Executive Officer of Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited w.e.f 03 August 2026. (Senior Managerial ....
Change in Management · 03 Aug 2026, 3:31 pm
Shilpa Medicare Appoints New CEO for its Biologics Subsidiary Shilpa Medicare has appointed Dr. Uday N. Harle as the CEO of its wholly-owned subsidiary, Shilpa Biologicals Private Limited, effective 03 Aug'26. Dr. Harle brings 24 years of biopharmaceutical experience, with over 18 years in biologics and biosimilars. His expertise spans the entire value chain, including R&D, clinical development, manufacturing, and P&L management. He previously held leadership roles at Artemis Medicare, Amneal Group, and Abbott, with extensive experience in developing biosimilars and novel biologics for global regulatory agencies like the USFDA and EMA.